ELVN

Enliven Therapeutics, Inc. ELVN

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-32.48M

Quarter to Jun 30

Free cash flow

$-18.63M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$4.05B total
FMR LLC
$508.77M+46.8%
ORBIMED ADVISORS LLC
$343.91M-14.9%
Polar Capital Holdings Plc
$326.35M+26.9%
BlackRock, Inc.
$221.25M+18.3%
Vestal Point Capital, LP
$203.00M+23.1%
Commodore Capital LP
$166.21M0.0%
PRICE T ROWE ASSOCIATES INC /MD/
$147.37M+2870.8%
VANGUARD CAPITAL MANAGEMENT LLC
$130.38MNew
CITADEL ADVISORS LLC
$105.00M+18.6%
Fairmount Funds Management LLC
$94.17M0.0%
Siren, L.L.C.
$90.05M+137.8%
Bellevue Group AG
$75.62M-35.8%
GEODE CAPITAL MANAGEMENT, LLC
$71.43M+32.0%
First Light Asset Management, LLC
$69.06M+574.1%
STATE STREET CORP
$61.59M+11.2%
Pictet Asset Management Holding SA
$58.96M+25.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$54.98MNew
Novo Holdings A/S
$50.75M-21.9%
First Turn Management, LLC
$48.43M+53.0%
SAMLYN CAPITAL, LLC
$46.32MNew
BAKER BROS. ADVISORS LP
$45.94M0.0%
Candriam S.C.A.
$45.92M+52.5%
Tri Locum Partners LP
$43.99MNew
ALLIANCEBERNSTEIN L.P.
$35.13M+16.1%
DIMENSIONAL FUND ADVISORS LP
$34.07M-1.5%
See all 214 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ELVN

Earnings Per Share

13fpro.ai/company/ELVN

Loading ratio trend…

ELVN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Enliven Therapeutics, Inc. (ELVN): stock profile, AI score and financials

Enliven Therapeutics, Inc. (ELVN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ELVN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Enliven Therapeutics, Inc. reports net income of $-32.5M, free cash flow of $-18.6M. Top institutional holders of ELVN by reported 13-F value include FMR, ORBIMED ADVISORS, Polar Capital Plc, based on the most recent SEC filings. ELVN trades on the Nasdaq exchange and files with the SEC under CIK 1672619. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Enliven Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1672619 →